Laboratory Medicine ›› 2025, Vol. 40 ›› Issue (12): 1153-1158.DOI: 10.3969/j.issn.1673-8640.2025.12.003
WANG Tian1, ZHANG Yun1, BAI Yi1, ZHAI Weibin2, ZHAO Hai1(
)
Received:2024-09-10
Revised:2025-05-01
Online:2025-12-30
Published:2025-12-26
Contact:
ZHAO Hai
CLC Number:
WANG Tian, ZHANG Yun, BAI Yi, ZHAI Weibin, ZHAO Hai. Roles of PIV,SII and NPAR in the diagnosis of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites[J]. Laboratory Medicine, 2025, 40(12): 1153-1158.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2025.12.003
| 组别 | 例数 | 性别 | 年龄/岁 | 合并症 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 男/[例(%)] | 女/[例(%)] | 消化道出血/[例(%)] | 栓塞/ [例(%)] | 肝性脑病/ [例(%)] | |||||||
| 无SBP组 | 393 | 197(50.13) | 196(49.87) | 59.0±13.5 | 107(27.23) | 34(8.65) | 25(6.36) | ||||
| SBP组 | 50 | 25(50.00) | 25(50.00) | 61.0±14.7 | 13(26.00) | 4(8.00) | 10(20.00) | ||||
| 统计值 | 0 | -0.140 | 0.034 | 0 | 9.542 | ||||||
| P值 | 0.986 | 0.888 | 0.854 | 1.000 | 0.002 | ||||||
| 组别 | 合并症 | 肝硬化病因 | |||||||||
| 肝肾综合征/[例(%)] | 肝衰竭/ [例(%)] | 乙型肝炎/ [例(%)] | 丙型肝炎/ [例(%)] | ALD/ [例(%)] | 酒精性肝硬化/ [例(%)] | 其他/ [例(%)] | |||||
| 无SBP组 | 3(0.76) | 21(5.34) | 243(61.83) | 39(9.92) | 51(12.98) | 32(8.14) | 28(7.12) | ||||
| SBP组 | 3(6.00) | 8(16.00) | 26(52.00) | 6(12.00) | 8(16.00) | 8(16.00) | 2(4.00) | ||||
| 统计值 | 5.607 | 6.584 | 4.479 | ||||||||
| P值 | 0.018 | 0.010 | 0.345 | ||||||||
| 组别 | 例数 | 性别 | 年龄/岁 | 合并症 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 男/[例(%)] | 女/[例(%)] | 消化道出血/[例(%)] | 栓塞/ [例(%)] | 肝性脑病/ [例(%)] | |||||||
| 无SBP组 | 393 | 197(50.13) | 196(49.87) | 59.0±13.5 | 107(27.23) | 34(8.65) | 25(6.36) | ||||
| SBP组 | 50 | 25(50.00) | 25(50.00) | 61.0±14.7 | 13(26.00) | 4(8.00) | 10(20.00) | ||||
| 统计值 | 0 | -0.140 | 0.034 | 0 | 9.542 | ||||||
| P值 | 0.986 | 0.888 | 0.854 | 1.000 | 0.002 | ||||||
| 组别 | 合并症 | 肝硬化病因 | |||||||||
| 肝肾综合征/[例(%)] | 肝衰竭/ [例(%)] | 乙型肝炎/ [例(%)] | 丙型肝炎/ [例(%)] | ALD/ [例(%)] | 酒精性肝硬化/ [例(%)] | 其他/ [例(%)] | |||||
| 无SBP组 | 3(0.76) | 21(5.34) | 243(61.83) | 39(9.92) | 51(12.98) | 32(8.14) | 28(7.12) | ||||
| SBP组 | 3(6.00) | 8(16.00) | 26(52.00) | 6(12.00) | 8(16.00) | 8(16.00) | 2(4.00) | ||||
| 统计值 | 5.607 | 6.584 | 4.479 | ||||||||
| P值 | 0.018 | 0.010 | 0.345 | ||||||||
| 组别 | 例数 | WBC计数/(×109L-1) | NEUT#/(×109L-1) | NEUT%/% | LYMPH#/(×109L-1) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 非SBP组 | 393 | 3.64(2.60~5.18) | 2.18(1.38~3.40) | 63.38(55.53~72.35) | 0.76(0.51~1.15) | ||||||||
| SBP组 | 50 | 8.15(4.36~10.76) | 5.81(3.48~8.015) | 74.45(61.28~80.60) | 0.82(0.47~1.27) | ||||||||
| Z值 | -6.211 | -7.052 | -4.427 | -0.771 | |||||||||
| P值 | <0.001 | <0.001 | <0.001 | 0.441 | |||||||||
| 组别 | LYMPH%/% | MO#/(×109L-1) | MONO%/% | PLT计数/(×109L-1) | CRP/(mg·L-1) | ||||||||
| 非SBP组 | 22.75(15.51~30.57) | 0.33(0.22~0.51) | 9.23(7.25~11.75) | 68(45~101) | 14.44(5.83~33.29) | ||||||||
| SBP组 | 13.62(7.84~22.62) | 0.68(0.34~1.05) | 10.19(6.85~13.99) | 81(55~133) | 36.86(10.70~85.09) | ||||||||
| Z值 | -5.082 | -5.362 | -0.815 | -1.419 | -2.96 | ||||||||
| P值 | <0.001 | <0.001 | 0.415 | 0.156 | 0.003 | ||||||||
| 组别 | Alb/(g·L-1) | TB/(μmol·L-1) | Cr/(μmol·L-1) | ALT/(U·L-1) | AST/(U·L-1) | ||||||||
| 非SBP组 | 28.70(25.50~33.00) | 26.31(17.40~40.42) | 56.06(44.00~68.74) | 24(16~43) | 38(25~65) | ||||||||
| SBP组 | 26.75(23.80~30.73) | 35.62(17.97~93.31) | 58.73(44.30~75.25) | 27(16~41) | 49(31~104) | ||||||||
| Z值 | -2.36 | -2.377 | -0.843 | -0.438 | -1.934 | ||||||||
| P值 | 0.018 | 0.017 | 0.399 | 0.661 | 0.053 | ||||||||
| 组别 | NLR | LMR | SII | PIV | NPAR | ||||||||
| 非SBP组 | 2.73(1.78~4.68) | 2.38(1.65~3.49) | 181.57 (98.47~337.98) | 62.53 (23.29~148.19) | 2.16(1.74~2.65) | ||||||||
| SBP组 | 5.98(2.81~10.45) | 1.36(0.84~2.33) | 625.13 (359.25~1 383.46) | 553.01 (188.7~1 000.35) | 2.72(2.30~3.40) | ||||||||
| Z值 | -5.399 | -5.446 | -7.002 | -7.377 | -4.882 | ||||||||
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | ||||||||
| 组别 | 例数 | WBC计数/(×109L-1) | NEUT#/(×109L-1) | NEUT%/% | LYMPH#/(×109L-1) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 非SBP组 | 393 | 3.64(2.60~5.18) | 2.18(1.38~3.40) | 63.38(55.53~72.35) | 0.76(0.51~1.15) | ||||||||
| SBP组 | 50 | 8.15(4.36~10.76) | 5.81(3.48~8.015) | 74.45(61.28~80.60) | 0.82(0.47~1.27) | ||||||||
| Z值 | -6.211 | -7.052 | -4.427 | -0.771 | |||||||||
| P值 | <0.001 | <0.001 | <0.001 | 0.441 | |||||||||
| 组别 | LYMPH%/% | MO#/(×109L-1) | MONO%/% | PLT计数/(×109L-1) | CRP/(mg·L-1) | ||||||||
| 非SBP组 | 22.75(15.51~30.57) | 0.33(0.22~0.51) | 9.23(7.25~11.75) | 68(45~101) | 14.44(5.83~33.29) | ||||||||
| SBP组 | 13.62(7.84~22.62) | 0.68(0.34~1.05) | 10.19(6.85~13.99) | 81(55~133) | 36.86(10.70~85.09) | ||||||||
| Z值 | -5.082 | -5.362 | -0.815 | -1.419 | -2.96 | ||||||||
| P值 | <0.001 | <0.001 | 0.415 | 0.156 | 0.003 | ||||||||
| 组别 | Alb/(g·L-1) | TB/(μmol·L-1) | Cr/(μmol·L-1) | ALT/(U·L-1) | AST/(U·L-1) | ||||||||
| 非SBP组 | 28.70(25.50~33.00) | 26.31(17.40~40.42) | 56.06(44.00~68.74) | 24(16~43) | 38(25~65) | ||||||||
| SBP组 | 26.75(23.80~30.73) | 35.62(17.97~93.31) | 58.73(44.30~75.25) | 27(16~41) | 49(31~104) | ||||||||
| Z值 | -2.36 | -2.377 | -0.843 | -0.438 | -1.934 | ||||||||
| P值 | 0.018 | 0.017 | 0.399 | 0.661 | 0.053 | ||||||||
| 组别 | NLR | LMR | SII | PIV | NPAR | ||||||||
| 非SBP组 | 2.73(1.78~4.68) | 2.38(1.65~3.49) | 181.57 (98.47~337.98) | 62.53 (23.29~148.19) | 2.16(1.74~2.65) | ||||||||
| SBP组 | 5.98(2.81~10.45) | 1.36(0.84~2.33) | 625.13 (359.25~1 383.46) | 553.01 (188.7~1 000.35) | 2.72(2.30~3.40) | ||||||||
| Z值 | -5.399 | -5.446 | -7.002 | -7.377 | -4.882 | ||||||||
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | ||||||||
| 因素 | 单因素分析 | 多因素分析 | |||
|---|---|---|---|---|---|
| OR①值(95%CI②) | P值 | OR①值(95%CI②) | P值 | ||
| 性别 | 0.995(0.552~1.792) | 0.986 | |||
| 年龄 | 1.002(0.980~1.023) | 0.888 | |||
| 消化道出血 | 1.065(0.545~2.081) | 0.854 | |||
| 肝性脑病 | 0.272(0.122~0.606) | 0.001 | 0.082(0.009~0.728) | 0.025 | |
| 栓塞 | 1.089(0.370~3.209) | 0.877 | |||
| 肝肾综合征 | 0.121(0.024~0.614) | 0.011 | 0.027(0~3.184) | 0.138 | |
| 肝衰竭 | 0.296(0.124~0.711) | 0.006 | 21.182(0.275~1 634.194) | 0.169 | |
| WBC计数 | 1.220(1.122~1.327) | <0.001 | 10.955(0.699~171.574) | 0.088 | |
| NEUT# | 1.506(1.337~1.695) | <0.001 | 0.069(0.002~2.291) | 0.135 | |
| NEUT% | 206.976(16.492~2 597.497) | <0.001 | 438 643(0~1.104×1016) | 0.332 | |
| LYMPH# | 1.370(0.898~2.090) | 0.144 | |||
| LYMPH% | 0(0~0.006) | <0.001 | 132 090(0.001~1.731×1012) | 0.216 | |
| MO# | 12.562(5.593~28.212) | <0.001 | 0.181(0~73.125) | 0.577 | |
| MO% | 8.577(0.009~8 199.421) | 0.539 | |||
| PLT计数 | 1.010(1.006~1.013) | <0.001 | 0.985(0.955~1.017) | 0.362 | |
| 因素 | 单因素分析 | 多因素分析 | |||
| OR①值(95%CI②) | P值 | OR①值(95%CI②) | P值 | ||
| CRP | 1.020(1.007~1.033) | 0.003 | 1.024(0.999~1.050) | 0.057 | |
| Alb | 0.954(0.910~1.001) | 0.055 | |||
| TB | 1.005(1.003~1.008) | <0.001 | 1.016(1.002~1.031) | 0.029 | |
| Cr | 1.000(0.996~1.004) | 0.919 | |||
| ALT | 1.000(0.998~1.002) | 0.981 | |||
| AST | 1.001(0.999~1.003) | 0.247 | |||
| NLR | 1.141(1.079~1.207) | <0.001 | 0.718(0.453~1.139) | 0.160 | |
| LMR | 0.446(0.318~0.626) | <0.001 | 0.653(0.156~2.727) | 0.559 | |
| SII | 1.002(1.001~1.003) | <0.001 | 1.003(0.996~1.011) | 0.339 | |
| PIV | 1.003(1.002~1.004) | <0.001 | 1.002(0.997~1.006) | 0.432 | |
| NPAR | 1.093(1.024~1.166) | 0.007 | 1.861(0.412~8.406) | 0.420 | |
| 因素 | 单因素分析 | 多因素分析 | |||
|---|---|---|---|---|---|
| OR①值(95%CI②) | P值 | OR①值(95%CI②) | P值 | ||
| 性别 | 0.995(0.552~1.792) | 0.986 | |||
| 年龄 | 1.002(0.980~1.023) | 0.888 | |||
| 消化道出血 | 1.065(0.545~2.081) | 0.854 | |||
| 肝性脑病 | 0.272(0.122~0.606) | 0.001 | 0.082(0.009~0.728) | 0.025 | |
| 栓塞 | 1.089(0.370~3.209) | 0.877 | |||
| 肝肾综合征 | 0.121(0.024~0.614) | 0.011 | 0.027(0~3.184) | 0.138 | |
| 肝衰竭 | 0.296(0.124~0.711) | 0.006 | 21.182(0.275~1 634.194) | 0.169 | |
| WBC计数 | 1.220(1.122~1.327) | <0.001 | 10.955(0.699~171.574) | 0.088 | |
| NEUT# | 1.506(1.337~1.695) | <0.001 | 0.069(0.002~2.291) | 0.135 | |
| NEUT% | 206.976(16.492~2 597.497) | <0.001 | 438 643(0~1.104×1016) | 0.332 | |
| LYMPH# | 1.370(0.898~2.090) | 0.144 | |||
| LYMPH% | 0(0~0.006) | <0.001 | 132 090(0.001~1.731×1012) | 0.216 | |
| MO# | 12.562(5.593~28.212) | <0.001 | 0.181(0~73.125) | 0.577 | |
| MO% | 8.577(0.009~8 199.421) | 0.539 | |||
| PLT计数 | 1.010(1.006~1.013) | <0.001 | 0.985(0.955~1.017) | 0.362 | |
| 因素 | 单因素分析 | 多因素分析 | |||
| OR①值(95%CI②) | P值 | OR①值(95%CI②) | P值 | ||
| CRP | 1.020(1.007~1.033) | 0.003 | 1.024(0.999~1.050) | 0.057 | |
| Alb | 0.954(0.910~1.001) | 0.055 | |||
| TB | 1.005(1.003~1.008) | <0.001 | 1.016(1.002~1.031) | 0.029 | |
| Cr | 1.000(0.996~1.004) | 0.919 | |||
| ALT | 1.000(0.998~1.002) | 0.981 | |||
| AST | 1.001(0.999~1.003) | 0.247 | |||
| NLR | 1.141(1.079~1.207) | <0.001 | 0.718(0.453~1.139) | 0.160 | |
| LMR | 0.446(0.318~0.626) | <0.001 | 0.653(0.156~2.727) | 0.559 | |
| SII | 1.002(1.001~1.003) | <0.001 | 1.003(0.996~1.011) | 0.339 | |
| PIV | 1.003(1.002~1.004) | <0.001 | 1.002(0.997~1.006) | 0.432 | |
| NPAR | 1.093(1.024~1.166) | 0.007 | 1.861(0.412~8.406) | 0.420 | |
| 项目 | AUC(95%CI) | 最佳临界值 | 敏感性/% | 特异性/% | 约登指数 |
|---|---|---|---|---|---|
| TB | 0.603(0.508~0.698) | 42.43 μmol·L-1 | 48.00 | 77.40 | 0.254 |
| CRP | 0.711(0.580~0.844) | 34.02 mg·L-1 | 52.63 | 84.85 | 0.375 |
| NEUT% | 0.692(0.613~0.771) | 72.50% | 58.00 | 75.57 | 0.336 |
| LYMPH% | 0.720(0.645~0.796) | 18.50% | 68.00 | 65.90 | 0.339 |
| NLR | 0.734(0.659~0.810) | 4.909 | 62.00 | 77.61 | 0.396 |
| LMR | 0.736(0.660~0.812) | 1.714 | 70.00 | 73.03 | 0.430 |
| SII | 0.804(0.733~0.874) | 353.800 | 76.00 | 76.84 | 0.528 |
| PIV | 0.820(0.745~0.895) | 171.000 | 80.00 | 77.61 | 0.576 |
| NPAR | 0.712(0.637~0.787) | 2.442 | 68.00 | 65.97 | 0.340 |
| 项目 | AUC(95%CI) | 最佳临界值 | 敏感性/% | 特异性/% | 约登指数 |
|---|---|---|---|---|---|
| TB | 0.603(0.508~0.698) | 42.43 μmol·L-1 | 48.00 | 77.40 | 0.254 |
| CRP | 0.711(0.580~0.844) | 34.02 mg·L-1 | 52.63 | 84.85 | 0.375 |
| NEUT% | 0.692(0.613~0.771) | 72.50% | 58.00 | 75.57 | 0.336 |
| LYMPH% | 0.720(0.645~0.796) | 18.50% | 68.00 | 65.90 | 0.339 |
| NLR | 0.734(0.659~0.810) | 4.909 | 62.00 | 77.61 | 0.396 |
| LMR | 0.736(0.660~0.812) | 1.714 | 70.00 | 73.03 | 0.430 |
| SII | 0.804(0.733~0.874) | 353.800 | 76.00 | 76.84 | 0.528 |
| PIV | 0.820(0.745~0.895) | 171.000 | 80.00 | 77.61 | 0.576 |
| NPAR | 0.712(0.637~0.787) | 2.442 | 68.00 | 65.97 | 0.340 |
| [1] | 中华医学会肝病学分会. 肝硬化腹水诊疗指南(2023年版)[J]. 中华肝脏病杂志, 2023, 31(8):813-826. |
| [2] | HE K, SI L, PAN X, et al. Preoperative systemic immune-inflammation index(SII)as a superior predictor of long-term survival outcome in patients with stage Ⅰ-Ⅱ gastric cancer after radical surgery[J]. Front Oncol, 2022,12:829689. |
| [3] |
YILMAZ M, BARAN A, YILMAZ M K. Predictive significance of inflammatory indexes in metastatic nonsmall cell lung cancer patients treated with platinum-doublet chemotherapy[J]. J Cancer Res Ther, 2022, 18(1):220-223.
DOI PMID |
| [4] |
JI J, WEI X, XUE B, et al. Predictive value of pan-immune inflammation value and systemic immune-inflammation index for identifying coronary vulnerable plaques:new insights from optical coherence tomography in acute coronary syndrome patients[J]. J Inflamm Res, 2024,17:10371-10382.
DOI URL |
| [5] | QIU S, JIANG Q, LI Y. The association between pan-immune-inflammation value and chronic obstructive pulmonary disease:data from NHANES 1999-2018[J]. Front Physiol, 2024,15:1440264. |
| [6] |
XU X Y, DING H G, LI W G, et al. Chinese guidelines on the management of liver cirrhosis(abbreviated version)[J]. World J Gastroenterol, 2020, 26(45):7088-7103.
DOI URL |
| [7] | ULLAH H. Correlation of clinically-suspected spontaneous bacterial peritonitis(SBP)with laboratory-confirmed SBP in portosystemic encephalopathy patients[J]. Cureus, 2022, 14(11):e31120. |
| [8] |
林奇龙, 陈琼娜, 李春儿, 等. 肝硬化并自发性腹膜炎腹水细菌谱及耐药性分析[J]. 检验医学, 2014, 29(3):301-302.
DOI |
| [9] |
ABDEL HAMMED M R, EL-AMIEN H A, ASHAM M N, et al. Can platelets indices and blood neutrophil to lymphocyte ratio be used as predictors for diagnosis of spontaneous bacterial peritonitis in decompensated post hepatitis liver cirrhosis?[J]. Egypt J Immunol, 2022, 29(4):12-24.
PMID |
| [10] |
HU Z, WANG J, XUE Y, et al. The neutrophil-to-albumin ratio as a new predictor of all-cause mortality in patients with heart failure[J]. J Inflamm Res, 2022,15:701-713.
DOI PMID |
| [11] |
XU M, HUAN J, ZHU L, et al. The neutrophil percentage-to-albumin ratio is an independent risk factor for poor prognosis in peritoneal dialysis patients[J]. Ren Fail, 2024, 46(1):2294149.
DOI URL |
| [12] |
WIEDERMANN C J. Hypoalbuminemia as surrogate and culprit of infections[J]. Int J Mol Sci, 2021, 22(9):4496.
DOI URL |
| [13] |
MOUSA N, SALAH M, ELBAZ S, et al. Neutrophil percentage-to-albumin ratio is a new diagnostic marker for spontaneous bacterial peritonitis:a prospective multicenter study[J]. Gut Pathog, 2024, 16(1):18.
DOI |
| [14] | 谭人杰, 徐佳丽, 孙长峰, 等. 肝硬化腹水并发自发性细菌性腹膜炎的临床危险因素分析及诊断模型构建[J]. 重庆医学, 2024, 53(6):872-876. |
| [15] | PAUL K, KAUR J, KAZAL H L. To study the incidence,predictive factors and clinical outcome of spontaneous bacterial peritonitis in patients of cirrhosis with ascites[J]. J Clin Diagn Res, 2015, 9(7):OC09-12. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||